792 related articles for article (PubMed ID: 10594855)
41. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
42. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
43. Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
Kotzsch M; Magdolen V; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Eckert AW; Luther T; Baretton G; Würl P; Taubert H
BMC Cancer; 2011 Jun; 11():273. PubMed ID: 21702998
[TBL] [Abstract][Full Text] [Related]
44. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
45. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
46. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
Chung HC; Rha SY; Park JO; Yoo NC; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Kim JJ
Breast Cancer Res Treat; 1998 May; 49(1):41-50. PubMed ID: 9694610
[TBL] [Abstract][Full Text] [Related]
47. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
48. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Konno H; Abe J; Kaneko T; Baba M; Shoji A; Sunayama K; Kamiya K; Tanaka T; Suzuki S; Nakamura S; Urano T
Jpn J Cancer Res; 2001 May; 92(5):516-23. PubMed ID: 11376560
[TBL] [Abstract][Full Text] [Related]
49. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
50. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
51. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
52. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
[TBL] [Abstract][Full Text] [Related]
53. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Taubert H; Würl P; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Meye A; Eckert AW; Holzhausen HJ; Magdolen V; Kotzsch M
Br J Cancer; 2010 Feb; 102(4):731-7. PubMed ID: 20051950
[TBL] [Abstract][Full Text] [Related]
54. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
55. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
56. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Konno H; Baba M; Shoji T; Ohta M; Suzuki S; Nakamura S
Clin Exp Metastasis; 2002; 19(6):527-34. PubMed ID: 12405290
[TBL] [Abstract][Full Text] [Related]
57. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
58. The urokinase plasminogen activator system: role in malignancy.
Duffy MJ
Curr Pharm Des; 2004; 10(1):39-49. PubMed ID: 14754404
[TBL] [Abstract][Full Text] [Related]
59. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
60. Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Sałuda-Gorgul A; Pytel J; Olborski B; Greger J
Z Naturforsch C J Biosci; 2002; 57(3-4):366-71. PubMed ID: 12064742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]